Feb 24 (Reuters) - Convatec lifted its medium-term organic revenue growth target on Tuesday, citing a strengthening medical product pipeline, after the British company posted a more than 12% rise in
Convatec Raises Medium‑Term Organic Revenue Target on Strong Pipeline
Convatec Growth Outlook and Financial Highlights
Feb 24 (Reuters) - Convatec lifted its medium-term organic revenue growth target on Tuesday, citing a strengthening medical product pipeline, after the British company posted a more than 12% rise in annual adjusted operating profit.
North America and Europe Focus
Advanced Wound Care Launches
Chronic Care Strategy and Expansion
The firm has pivoted into a pure-play chronic care company by streamlining its operations and launching new products, such as advanced wound care dressing, while expanding in North America and Europe.
Tariff Headwinds
InnovaMatrix Revenue Drag
Margin and Cost Outlook
Convatec expects its first-half adjusted operating margin to grow slightly from a year earlier, though lower revenue from its InnovaMatrix skin‑graft product and incremental tariff costs will likely weigh on its performance.
Adjusted Operating Profit Performance
The company, which also makes catheters and drug delivery systems, reported an annual adjusted operating profit of $544 million, compared with $485 million a year earlier, with steady demand in its chronic‑care portfolio and new product launches supporting the growth.
FY2026 Organic Sales Guidance
Medium‑Term Revenue Target Raised
The company reiterated that organic sales would grow 5% to 7%, excluding InnovaMatrix, for fiscal 2026. Convatec now sees its medium‑term organic revenue growth in the range of 6% to 8% compared with 5%–7% previously expected.
Reporting and Editing Credits
(Reporting by Nithyashree R B in Bengaluru; Editing by Mrigank Dhaniwala and Subhranshu Sahu)
